Any thoughts on whether the current share price takes into account the acceptance of the Biologics License Application (BLA) for trastuzumab emtansine (T-DM1)? With Roche currently having 3 of the top 10 selling drugs, the approval of T-DM1 in the first half of 2013 will further strengthen their position within Oncology. Biosimiliar activity for Herceptin and Rituxan also appears to be muted at this time.
Sentiment: Buy